EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy for individuals with liver disease Glasgow, Scotland โ 11 …